Castle Biosciences Reports Third-Quarter Loss of $4.1 Million

Castle Biosciences’ third-quarter revenue rose 23.9% year over year, while its net loss widened. Growth was led by non-dermatologic tests, particularly TissueCypher, whose report volume increased 47%; lower DecisionDx-SCC revenue partially offset the increase. Higher operating expenses and a $3.4 m…